These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

948 related items for PubMed ID: 17418683

  • 1. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB, Coffman TM.
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [Abstract] [Full Text] [Related]

  • 2. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN.
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 6. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [Abstract] [Full Text] [Related]

  • 7. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
    Fronczyk A, Majkowska L.
    Przegl Lek; 2007 Dec; 64(2):81-5. PubMed ID: 17892038
    [Abstract] [Full Text] [Related]

  • 8. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK, Epstein M.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract] [Full Text] [Related]

  • 9. Role of angiotensin II in diabetic nephropathy.
    Kennefick TM, Anderson S.
    Semin Nephrol; 1997 Sep; 17(5):441-7. PubMed ID: 9316212
    [Abstract] [Full Text] [Related]

  • 10. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P, Parving HH, de Zeeuw D.
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract] [Full Text] [Related]

  • 11. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL, Gleason BL.
    Ann Pharmacother; 2004 Sep; 38(7-8):1278-82. PubMed ID: 15187210
    [Abstract] [Full Text] [Related]

  • 12. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA, Götz AK, Krüger B, Hösl M, Schmitz G, Riegger GA, Krämer BK.
    Eur J Med Res; 2005 Apr 20; 10(4):161-8. PubMed ID: 15946912
    [Abstract] [Full Text] [Related]

  • 13. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function].
    Ritz E.
    MMW Fortschr Med; 2004 Sep 16; 146(38):12. PubMed ID: 15532423
    [No Abstract] [Full Text] [Related]

  • 14. Treating diabetic nephropathy: unfinished success is not failure.
    Lewis J.
    Clin J Am Soc Nephrol; 2007 May 16; 2(3):407-9. PubMed ID: 17699442
    [No Abstract] [Full Text] [Related]

  • 15. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I, Degrell P, Komáromy A, Molnár GA, Wagner Z, Wagner L, Mazák I, Nagy J.
    Orv Hetil; 2003 Mar 30; 144(13):613-9. PubMed ID: 12728786
    [Abstract] [Full Text] [Related]

  • 16. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R, Faraone R, Ruggenent P, Remuzzi G.
    J Nephrol; 2002 Mar 30; 15(4):428-30. PubMed ID: 12243375
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G, Sciarretta S, Facciolo C, Volpe M.
    Expert Rev Cardiovasc Ther; 2007 Jul 30; 5(4):767-76. PubMed ID: 17605654
    [Abstract] [Full Text] [Related]

  • 18. Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
    Bakris G.
    Am J Cardiol; 2010 Jan 04; 105(1 Suppl):21A-9A. PubMed ID: 20102970
    [Abstract] [Full Text] [Related]

  • 19. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
    Barnas U, Mayer G.
    Wien Klin Wochenschr; 1995 Jan 04; 107(1):10-4. PubMed ID: 7871784
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S, Aurell M.
    J Am Soc Nephrol; 1990 Nov 04; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.